Table 1.
Baseline characteristics at the time of the index injection.
| Main cohort (N = 1190 eyes from 1065 patients) | OCT markers of lesion activity sub-cohort (N = 321 eyes from 307 patients) | Retreatment criteria sub-cohort (N = 301 eyes from 279 patients) | |
|---|---|---|---|
| Age at index (patient) | |||
| Mean years (SD) | 79.1 (6.3) | 79.5 (6.4) | 80.2 (6.5) |
| Gender (patient): (n, %) | |||
| Male | 404 (37.9%) | 119 (38.8%) | 113 (40.5%) |
| Female | 661 (62.1%) | 188 (61.2%) | 166 (59.5%) |
| Year of index injection (eye): (n, %) | |||
| 2010 | 49 (4.1%) | 3 (0.9%) | 0 (0.0%) |
| 2011 | 121 (10.2%) | 6 (1.9%) | 0 (0.0%) |
| 2012 | 130 (10.9%) | 12 (3.7%) | 0 (0.0%) |
| 2013 | 138 (11.6%) | 19 (5.9%) | 0 (0.0%) |
| 2014 | 206 (17.3%) | 72 (22.4%) | 8 (2.7%) |
| 2015 | 205 (17.2%) | 75 (23.4%) | 106 (35.2%) |
| 2016 | 192 (16.1%) | 77 (24.0%) | 108 (35.9%) |
| 2017 | 149 (12.5%) | 57 (17.8%) | 79 (26.2%) |
| Eyes treated (patient): (n, %) | |||
| Unilateral | 940 (88.3%) | 293 (95.4%) | 257 (92.1%) |
| Bilateral | 125 (11.7%) | 14 (4.6%) | 22 (7.9%) |
| Eyes treated (patient): (n, %) | |||
| Left | 431 (40.5%) | 120 (39.1%) | 126 (45.2%) |
| Right | 509 (47.8%) | 173 (56.4%) | 131 (47.0%) |
| Both | 125 (11.7%) | 14 (4.6%) | 22 (7.9%) |
| VA study eye ETDRS lettersa (eye) | |||
| Mean (SD) | 50.8 (15.3) | 54.7 (8.7) | 51.0 (15.3) |
ETDRS Early Treatment Diabetic Retinopathy Study, OCT optical coherence tomography, SD standard deviation.
aVA at index or in the 30-day period before the index injection.